聚乙二醇干扰素-2a联合利巴韦林治疗慢性丙型肝炎7例疗效分析
Ribavirin combined with interferon for treatment of chronic hepatitis C: a report of 7 cases
-
摘要: 目的:根据慢性丙型肝炎病毒(HCV)RNA基因型和治疗早期病毒学应答制定干扰素(IFN)联合利巴韦林(RBV)的治疗方案,并探讨其临床疗效。方法:应用基因型特异性引物反转录PCR法检测患者的基因型。基因1型:RBV1.0~1.2 g/d口服,聚乙二醇干扰素-2a(PEG-IFN-2a)180g,皮下注射,每周1次,疗程48周;基因2/3型:RBV 800 mg/d,PEG-IFN-2a180g,皮下注射,每周1次,疗程24周。治疗4周、12周及疗程结束24周检测HCV RNA载量,根据4周、12周检测HCVRNA的结果适当调整治疗疗程。结果:7例患者均获得了持续病毒学应答。结论:根据HCV RNA基因型及治疗早期(4周、12周)和24周的病毒学应答制定治疗方案,是一种有效的方法。Abstract: Objective: To evaluate the therapy of ribavirin(RBV) plus interferon(IFN) which was made according to the genotype of hepatitis C virus(HCV) and virological response for treatment of hepatitis C.Methods: The genotype of 7 patients with chronic hepatitis C was detected by reverse-transcript PCR.The patients with genotype 1 received the therapy of RBV 1.0-1.2 g / d,P.O combined with per week pegylated interferon ɑ-2a(PEG-IFN ɑ-2a) subcutaneous injection,180 g for 48 weeks,and patients with genotype 2 /3 were treated by RBV(800 mg / d,P.O) combined with per week PEG-IFN ɑ-2a subcutaneous injection,180 g for 24 weeks.The load of HCV RNA was detected after 4,12 and 24 week during the therapy.The treatment period was modified according to the serum levels of HCV RNA.Results: Sustained virological response was observed in all the 7 patients.Conclusions: Modifying the therapy for patients with chronic hepatitis according to the genotype of HCV and the virological response is of vital importance to enhance the antiviral efficacy.